<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803296</url>
  </required_header>
  <id_info>
    <org_study_id>BMI-INK</org_study_id>
    <nct_id>NCT00803296</nct_id>
  </id_info>
  <brief_title>Incretin Effect in Lean and Obese Subjects</brief_title>
  <acronym>BMI-INK</acronym>
  <official_title>The Impact of Obesity and Insulin Resistance on the Incretin Effect in Patients With Type 2 Diabetes and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incretin effect is markedly reduced in patients with type 2 diabetes. Data support the
      notion that this deficiency is a consequence of the diabetic state. However, the impact of
      insulin resistance on the incretin effect in obese individuals who uphold a normal glucose
      tolerance (NGT) despite their insulin resistant state remains to be elucidated. The primary
      aim of the present study is to evaluate the separate impact of one of the cornerstones of
      type 2 diabetic pathophysiology, namely insulin resistance, on the incretin effect in lean
      and obese patients with type 2 diabetes and in two matched normal-glucose tolerant groups of
      healthy control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incretin effect</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Incretin Effect</condition>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Obese patients with type 2 diabetes</arm_group_label>
    <description>Patients with type 2 diabetes and BMI&gt;33</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese subjects with normal glucose tolerance</arm_group_label>
    <description>Subjects with normal glucose tolerance and BMI&gt;33</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean subjects with type 2 diabetes</arm_group_label>
    <description>Patients with type 2 diabetes and BM&lt;25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean subjects with normal glucose tolerance</arm_group_label>
    <description>Subjects with normal glucose tolerance and BM&lt;25</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glucose tolerance test (OGTT)</intervention_name>
    <arm_group_label>Obese patients with type 2 diabetes</arm_group_label>
    <arm_group_label>Obese subjects with normal glucose tolerance</arm_group_label>
    <arm_group_label>Lean subjects with type 2 diabetes</arm_group_label>
    <arm_group_label>Lean subjects with normal glucose tolerance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isoglycemic intravenous glucose infusion</intervention_name>
    <arm_group_label>Obese patients with type 2 diabetes</arm_group_label>
    <arm_group_label>Obese subjects with normal glucose tolerance</arm_group_label>
    <arm_group_label>Lean subjects with type 2 diabetes</arm_group_label>
    <arm_group_label>Lean subjects with normal glucose tolerance</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Lean and obese patients with type 2 diabetes; and matched healthy control subjects.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes for at least 3 months

          -  Normal blood hemoglobin

          -  Informed consent

        Exclusion Criteria:

          -  Liver disease

          -  Diabetic nephropathy

          -  Treatment with medication that can not be stopped for 12 hours
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Vilsb√∏ll, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gentofte Hospital, University of Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Filip K. Knop, MD PhD</name_title>
    <organization>University Hospital, Gentofte, Copenhagen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

